Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
Readen Holding Corporation (OTCQB: RHCO) is a listed venture capital corporation with over 30 years of activity. The company trading just above its 52-week low offers a significant upside thanks to robust services diversification and revenues expected to ramp up significantly in Q4 2023. The company, now traded on the OTCQB, already showed an increase in revenues of 410% compared to the same period in 2021. You can see the potential in the company. In this article, we will explain in this article why we are excited about Readen Holding and why 2024 will be prolific for shareholders.
Readen holding and its 410%
You haven’t seen it wrong, Readen Holding had a 410% increase year-over-year. And this is probably why we love fintech companies, as they can expand fast and, consequently, witness strong revenue growth. How did the company achieve this? It is thanks to the fact that the company is working with new payment providers, and its flagship product OkePay is on the right track to develop more robust and vigorous revenues. In the latest financial statement, the product had a setback in revenue for only five weeks so we can consider more considerable leverage in the following financial statement. Readen Holding also has developed OkePartners ( a discount referral platform) and started recruiting for Oke Travel Club, which will boost its revenues.
Readen’s relationship with IT Star
On October 19, the company stated it sold 20% of its subsidiary Ares Technology, which holds the E-commerce businesses Neckermann Direct and Two Percent, to IT Star Limited as a strategic move to IT Star Limited. IT Star is wholly owned by Cocoon Limited, a company listed on the Hong Kong Exchanged (HK:0428.HK). The transaction will be paid with a bond of Shenzhen Huaqin Agriculture Technology Company Limited, which had a value of USD $3.7M on June 30, 2022, and has an 8.5% annual fixed interest. The bond will mature in December 2023, and Readen will collect USD $4.19M. As a reminder, IT Star has been a strategic partner of Readen Holding as it owns 8.6% of Readen’s share issued.
About Huaqin Agricultural, it is a private entity established in China. Huaqin Agricultural is engaged in the technological development of agricultural and biological products, retail, and food wholesale. This transfer is important for Readen because it will enable the company to build a synergy with Huagin Agricultural’s tech team, which will enhance the development of Neckermann Direct (www.neckermanndirect.eu) and Two Percent (www.twopercent.hk), as well as the Company’s B2B food trading platform Fligro Limited (www.fligrofood.com).
What others news occurred with Readen?
The company is pretty transparent, and you can see all its moves on Readen Holding’s news section. One exciting piece of information is the “Yield Sign” has been removed from the OTC Markets. It occurred because of the adjustment of the attorney opinion letter, resulting in a delay in submitting the letter, forcing the OTC Markets to label RHCO a “Yield Sign” since the end of September. It is a positive sign for investors as the company is considered healthy. Even though the company got a bad reputation for a short time, everything went back to normal, with RHCO moving back to the “Pink Current” tier.
Another relevant piece of information is that a new Fintech business director has been announced. Indeed, Simon Tang (former project director of Huawei Technologies) is now the director of OkePay NZ. Simon Tang is an IT and Telecom expert with over 20 years of experience in large-scale project management, corporate strategies, business development, and consultancy. He has held various top executive positions in multinational corporations, prominent in the telecom and digital transformation sectors.
“We are so excited to have Simon join our team. He will be the leading man of our Fintech business, and we are confident that he will bring new insights and visions to our OkePay and Oke Partners initiatives and fully realize their potential. And his global experience and connections also give us greater power to expand the coverages of OkePay and OkeApp. We see Simon as one of the most important additions to the RHCO team yet.”
Richard Klitsie, CEO
Even if this is recent news, Readen Holding is now involved in the marble industry with a transaction with Angelo Mermer Marble. The exciting side is the transaction was paid by convertible bond of Angelo Mermer and was converted at a 50% discount into 200 shares of ANGELO MERMER, which equals 5% of total ANGELO MERMER shares. According to ANGELO MERMER, its economically recoverable high-grade reserve amount to 1 million tons. Its total onyx reserve accounts for 5% of the world’s total onyx reserves. Based on the valuation report of Baker Tilly as of March 31, 2021, the total investment value of ANGELO MERMER was calculated at USD 1 billion.
Bottom Line
Readen Holding (OTCQB: RHCO) appears to be more undervalued. The company announced several news, and the potential upside is endless. The following financial statement will prove the company’s future success, and adding Readen to the portfolio looks like a substantial investment. Keep also in mind that Readen is well diversified, with an involvement in the marble industry.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
All Articles
The latest
Alset Capital Inc. (TSXV: KSUM) : Innovative Advancements Together with Nvidia
Discover The Phillips Township Property from Golden Rapture (CSE:GLDR)
NurExone Unlocks Several Milestones Since March 2024 (TSXV: NRX, FSE: J90, NRX.V)
Subscribe
©2024 10xAlerts